{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T08:39:19Z","timestamp":1648629559121},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1097\/mca.0000000000000694","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T14:17:00Z","timestamp":1548512220000},"page":"177-182","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention"],"prefix":"10.1097","volume":"30","author":[{"given":"Benjamin Z.","family":"Galper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallav","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Secemsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda R.","family":"Valsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210204","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Schupke","year":"2015","journal-title":"Eur Heart J"},{"key":"R2-3-20210204","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R3-3-20210204","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R4-3-20210204","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"R5-3-20210204","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R6-3-20210204","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"R7-3-20210204","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/clc.22512","article-title":"Clinical outcome of first- vs second-generation DES according to DAPT duration: results of ARCTIC-generation","volume":"39","author":"Collet","year":"2016","journal-title":"Clin Cardiol"},{"key":"R8-3-20210204","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcin.2013.09.008","article-title":"Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY)","volume":"7","author":"Valgimigli","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"R9-3-20210204","doi-asserted-by":"crossref","first-page":"222.e5","DOI":"10.1016\/j.ahj.2014.11.002","article-title":"Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents","volume":"169","author":"Garg","year":"2015","journal-title":"Am Heart J"},{"key":"R10-3-20210204","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"key":"R11-3-20210204","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-3-20210204","first-page":"1034","article-title":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11\u2009473 patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur Heart J"},{"key":"R13-3-20210204","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R14-3-20210204","first-page":"1373","article-title":"Duration of dual antiplatelet therapy after drug-eluting stents","volume":"372","author":"Mauri","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-3-20210204","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jtcvs.2016.07.044","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"152","author":"Levine","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R16-3-20210204","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-3-20210204","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R18-3-20210204","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"R19-3-20210204","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0735-1097(02)02862-0","article-title":"Long-term follow-up of coronary artery disease presenting in young adults","volume":"41","author":"Cole","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R20-3-20210204","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.amjcard.2003.07.022","article-title":"Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non-ST-elevation myocardial infarction","volume":"92","author":"Lloyd-Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"R21-3-20210204","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2008.01.042","article-title":"Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model","volume":"51","author":"Garg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R22-3-20210204","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"R23-3-20210204","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1161\/hc5001.100794","article-title":"Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial","volume":"104","author":"Cohen","year":"2001","journal-title":"Circulation"},{"key":"R24-3-20210204","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1161\/CIRCULATIONAHA.107.735340","article-title":"Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk","volume":"117","author":"Greving","year":"2008","journal-title":"Circulation"},{"key":"R25-3-20210204","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/CIRCULATIONAHA.110.985655","article-title":"Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation","volume":"123","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"R26-3-20210204","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1525-1497.1998.00246.x","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"13","author":"Augustovski","year":"1998","journal-title":"J Gen Intern Med"},{"key":"R27-3-20210204","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/archinte.1996.00440150083009","article-title":"The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life","volume":"156","author":"Gage","year":"1996","journal-title":"Arch Intern Med"},{"key":"R28-3-20210204","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N Engl J Med"},{"key":"R29-3-20210204","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ahj.2005.02.028","article-title":"The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry","volume":"151","author":"Kauf","year":"2006","journal-title":"Am Heart J"},{"key":"R30-3-20210204","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/CIRCOUTCOMES.110.960187","article-title":"Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice","volume":"4","author":"Schafer","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R31-3-20210204","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jacc.2014.11.034","article-title":"Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study","volume":"65","author":"Cowper","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R32-3-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann Intern Med"},{"key":"R33-3-20210204","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.109.878017","article-title":"Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial","volume":"121","author":"Pocock","year":"2010","journal-title":"Circulation"},{"key":"R34-3-20210204","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jcin.2012.05.010","article-title":"Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients","volume":"5","author":"Rao","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"R35-3-20210204","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"R36-3-20210204","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"R37-3-20210204","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point","volume":"51","author":"Ndrepepa","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R38-3-20210204","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jacc.2011.07.021","article-title":"Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial","volume":"58","author":"Suh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R39-3-20210204","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"R40-3-20210204","doi-asserted-by":"crossref","first-page":"k3793","DOI":"10.1136\/bmj.k3793","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial.","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:43:22Z","timestamp":1620960202000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019501-201905000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000694","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}